<div id="readability-page-1">12:14 PM EST, 01/23/2026 (MT Newswires) -- Abbott Laboratories ( ABT ) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparisons, RBC Capital Markets said.The brokerage said in a Thursday note that the near-term challenges in Diagnostics from Chinese volume-based procurement and internal initiatives in Nutrition are likely to persist in the first half. However, RBC said the issues are temporary.Abbott guided to 2026 organic revenue growth of 6.5% to 7.5%, which is below RBC and consensus estimates. The company also projected adjusted EPS of $5.55 to $5.80 roughly in line with forecasts.MedTech grew 10.4% organically in Q4, which was slightly below RBC's estimate. Established Pharmaceuticals rose 7%. These results supported total organic growth of 3.8% but excluding COVID-related sales.The brokerage said that the expectations have now reset and upside surprises in the second half could come from the US launch of the VOLT system in Electrophysiology. Additional growth could come from Structural Heart, Diabetes and potential M&amp;A in Diagnostics and MedTech.Management remains committed to delivering double-digit EPS growth and cited confidence in operational execution and long-term demand trends, according to the note.RBC maintained an outperform rating for Abbott and lowered its price target to $135 from $147.Price: 107.66, Change: -0.95, Percent Change: -0.88 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

美國制藥 ETF - iShares

雅培

醫療業 ETF - SPDR

標普全球醫療股指數 ETF - iShares

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

醫療業 ETF - Vanguard

基因改革 ETF - ARK

根據 RBC 資本市場的分析，雅培預計在 2026 年下半年將實現增長，這得益於新產品的推出以及其營養和診斷部門的復甦。儘管面臨短期挑戰，該公司預計有機收入增長將達到 6.5% 至 7.5%，調整後的每股收益為 5.55 美元至 5.80 美元。RBC 維持 “跑贏大盤” 的評級，但將其目標價從 147 美元下調至 135 美元。醫療技術和成熟藥品部門顯示出增長，推動了總有機增長達到 3.8%

Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says

fidelity

Abacus Global

RBC 表示，雅培預計下半年的增長將受到產品發佈和營養恢復的推動